HC Wainwright restated their buy rating on shares of Gain Therapeutics (NASDAQ:GANX – Free Report) in a report issued on Wednesday morning, Benzinga reports. HC Wainwright currently has a $9.00 target price on the stock. GANX has been the topic of a number of other reports. Chardan Capital reissued a buy rating and set a […]
Gain Therapeutics, Inc. (NASDAQ:GANX – Get Free Report) saw a significant growth in short interest in the month of April. As of April 15th, there was short interest totalling 149,600 shares, a growth of 8.3% from the March 31st total of 138,100 shares. Currently, 1.1% of the company’s shares are short sold. Based on an […]
HC Wainwright Reiterates Buy Rating for Gain Therapeutics (NASDAQ:GANX) themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Gain Therapeutics (NASDAQ:GANX) Receives Buy Rating from HC Wainwright theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Gain Therapeutics, Inc. (NASDAQ:GANX – Get Free Report) Director Jeffrey Scott Riley bought 30,000 shares of the firm’s stock in a transaction on Thursday, March 28th. The shares were purchased at an average price of $3.86 per share, for a total transaction of $115,800.00. Following the completion of the transaction, the director now owns 30,000 […]